Abstract
Survival analysis is essential for predicting patient outcomes and guiding personalized cancer treatments. While multi-omics data offers valuable insights, its high dimensionality complicates analysis and clinical application. Many studies still rely on the traditional Cox proportional hazards model, with limited exploration of alternative survival algorithms or robust feature selection methods. Few frameworks effectively integrate features across multiple omics modalities. To address these issues, we developed PRISM (PRognostic marker Identification and Survival Modelling through Multi-omics Integration), a comprehensive framework designed to improve survival predictions and identify key prognostic markers. PRISM systematically compares various feature selection methods and survival models and employs a robust pipeline that selects features from single-omics data, integrating them through feature-level fusion and multi-stage refinement. Applied to TCGA data for Breast Invasive Carcinoma (BRCA), Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC), Ovarian Serous Cystadenocarcinoma (OV) and Uterine Corpus Endometrial Carcinoma (UCEC), PRISM demonstrated that integrating DNA methylation, miRNA, and copy number variation data provided complementary information, significantly outperforming other modality combinations in three cancers (BRCA: C-index 0.77; CESC: 0.80; UCEC: 0.76). Pan-cancer analysis further revealed shared oncogenic pathways and therapeutic targets. PRISM provides a scalable, generalizable solution for multi-omics integration, advancing cancer research and precision medicine.
Key Points
Advancing Multi-Omics Survival Modelling – PRISM introduces a robust computational framework that enhances survival predictions and identifies key prognostic markers by systematically integrating multi-omics data.
Rigorous Feature Selection and Benchmarking – PRISM systematically evaluates multiple feature selection techniques and survival models using a voting-based approach to improve methodological robustness.
Optimized and Cost-Effective Signature Panel – By employing recursive feature elimination (RFE), PRISM minimizes the number of selected biomarkers, improving cost-effectiveness while maintaining high predictive accuracy for clinical applications.
Comprehensive Multi-Omics Integration – PRISM enables the fusion of features across diverse omics modalities using single-stage and two-tier refinement strategies, optimizing the final prognostic signature for maximum predictive power.
Scalability and Clinical Relevance – PRISM is generalizable beyond TCGA datasets, making it applicable to large-scale multi-omics studies with broad clinical and biomedical implications for personalized medicine and cancer research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TCGA Data from the GDC Portal
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated All Figures, Updated content for all sections
Data Availability
All datasets used in this study are publicly accessible through The Cancer Genome Atlas (TCGA) data portal. The PRISM pipeline, along with its documentation, is available at the following repository: https://github.com/VafaeeLab/PRISM/.
